Tyra BiosciencesTYRA -0.50%28 3-Year RORE % is 9.11 as of Mar. 2026. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,295 Biotechnology companies, Tyra Biosciences ranks better than 72.74% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Tyra Biosciences's 3-Year RORE % for the quarter that ended in Mar. 2026 was 9.11%.
The industry rank for Tyra Biosciences's 3-Year RORE % or its related term are showing as below:
TYRA's 3-Year RORE % is ranked better than 72.74% of 1295
companies
in the Biotechnology industry
Industry Median: -11.53
vs TYRA: 9.11
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Tyra Biosciences 3-Year RORE % Related Terms
Tyra Biosciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYRA vs SION, IOVA, SNDX: 3-Year RORE % Comparison
For the Biotechnology subindustry, Tyra Biosciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Tyra Biosciences (TYRA) has a 3-Year RORE % of 9.11 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Tyra Biosciences and its competitors. According to the industry distribution chart, Tyra Biosciences ranks #353 out of 1295 companies in the Biotechnology industry, placing it in the top 27.3%.
Is Tyra Biosciences' 3-Year RORE % too high?
Tyra Biosciences' current 3-Year RORE % is 9.11. Based on the distribution chart, Tyra Biosciences ranks #353 out of 1295 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' 3-Year RORE % compare to SION and IOVA?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #353 out of 1295 companies for 3-Year RORE %. This puts Tyra Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Tyra Biosciences and its competitors. Tyra Biosciences's current 3-Year RORE % is 9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current 3-Year RORE % of 9.11. The current 3-Year RORE % is 9.11. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current 3-Year RORE % is 9.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score
Get the complete analysis for TYRA
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
